<DOC>
	<DOCNO>NCT01749787</DOCNO>
	<brief_summary>The purpose study determine safety tolerability PRTX-100 various dos give 5 time weekly interval patient active rheumatoid arthritis take methotrexate leflunomide . The drug administer physician 's office via intravenous infusion . PRTX-100 may effective rheumatoid arthritis suppress immune response . PRTX-100 highly-purified bacterial protein call Staphylococcal Protein A . In study , cohorts patient active RA receive sequentially high dose PRTX-100 . There inactive placebo cohort comparison . Patients attain low RA disease activity , commonly used measure , leave study 3 month first dose study drug .</brief_summary>
	<brief_title>Safety Study PRTX-100 With Methotrexate Leflunomide Treat Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Leflunomide</mesh_term>
	<criteria>Active RA disease duration le 6 month Concomitant stable methotrexate leflunomide therapy Diagnosis inflammatory arthritis ACR Functional Classification IV Significant systemic involvement secondary RA ( except secondary Sjogren 's syndrome ) History clincally significant hypogammaglobulinemia , common variable immunodeficiency , humeral immunodeficientncy History active tuberculosis , prothrombotic disorder , venous thrombosis require anticoagulation , substance abuse , serious psychiatric condition History allergy hypersensitivity aspirin nonsteroidal cyclooxygenase inhibitor , Staphylococcal protein A History presence malignancy ( except surgically treat basal squamous cell carcinoma skin least 3 month prior start study medication ) Uncontrolled diabetes Type 1 diabetes Unstable ischemic heart disease Serious active recurrent infection , hepatic cirrhosis , medically unstable condition Systemic autoimmune disease RA ( systemic lupus erythematosus , scleroderma , inflammatory bowel disease , inflammatory myopathy ) Positive HIV , hepatitis B surface antigen , hepatitis C antibody Pregnant nursing female Inadequate hepatic , renal , hematologic function Receipt live vaccine within 5 week start study medication Concomitant administration biologic nonbiologic DMARDS , corticosteroid , antiCD20 antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>arthritis</keyword>
	<keyword>rheumatoid</keyword>
	<keyword>methotrexate</keyword>
	<keyword>leflunomide</keyword>
</DOC>